Gunilla Rask
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gunilla Rask has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Malin Sund
Department of Gastroenterological Surgery University of Helsinki and Helsinki University Hospital Helsinki Finland
6 shared publications Anoosheh Nazemroaya
Department of Medical Biosciences/Pathology, Umeå University, Umeå, Sweden
3 shared publications- Fredrik Wärnberg
Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , Gothenburg
3 shared publications - Aki Manninen
Disease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine, Biocenter Oulu, University of Oulu, Oulu, Finland
2 shared publications Carl Blomqvist
Department of Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
2 shared publicationsCharlotta Wadsten
Department of Surgery and Perioperative Sciences/Surgery, Umeå University, Umeå, Sweden
2 shared publications
Latest Publications
- Open Access
- 12 June 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (15)
Corrigendum to Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models
- 12 June 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (15)
Open AccessCorrigendum to Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models
- Open Access
- 31 January 2024
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 111 (2)
Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case–control study
Background: Studies identifying risk factors for death from breast cancer after ductal carcinoma in situ (DCIS) are rare. In this retrospective nested case–control study, clinicopathological factors in women treated for DCIS and who died from breast cancer were compared with those of patients with DCIS who were free from metastatic disease. Methods: The study included patients registered with DCIS without invasive carcinoma in Sweden between 1992 and 2012. This cohort was linked to the National Cause of Death Registry. Of 6964 women with DCIS, 96 were registered with breast cancer as cause of death (cases). For each case, up to four controls (318; women with DCIS, alive and without metastatic breast cancer at the time of death of the corresponding case) were selected randomly by incidence density sampling. Whole slides of tumour tissue were evaluated for DCIS grade, comedo necrosis, and intensity of periductal lymphocytic infiltrate. Composition of the immune cell infiltrate, expression of oestrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and proliferation marker Ki-67 were scored on tissue microarrays. Clinical information was obtained from medical records. Information on date, site, and histological characteristics of local and distant recurrences was obtained from medical records for both cases and controls. Results: Tumour tissue was analysed from 65 cases and 195 controls. Intense periductal lymphocytic infiltrate around DCIS was associated with an increased risk of later dying from breast cancer (OR 2.21. 95% c.i. 1.01 to 4.84). Tumours with more intense lymphocytic infiltrate had a lower T cell/B cell ratio. None of the other biomarkers correlated with increased risk of breast cancer death. Conclusion: The immune response to DCIS may influence the risk of dying from breast cancer.
- 31 January 2024
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 111 (2)
Open AccessImmune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case–control study
Background: Studies identifying risk factors for death from breast cancer after ductal carcinoma in situ (DCIS) are rare. In this retrospective nested case–control study, clinicopathological factors in women treated for DCIS and who died from breast cancer were compared with those of patients with DCIS who were free from metastatic disease. Methods: The study included patients registered with DCIS without invasive carcinoma in Sweden between 1992 and 2012. This cohort was linked to the National Cause of Death Registry. Of 6964 women with DCIS, 96 were registered with breast cancer as cause of death (cases). For each case, up to four controls (318; women with DCIS, alive and without metastatic breast cancer at the time of death of the corresponding case) were selected randomly by incidence density sampling. Whole slides of tumour tissue were evaluated for DCIS grade, comedo necrosis, and intensity of periductal lymphocytic infiltrate. Composition of the immune cell infiltrate, expression of oestrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and proliferation marker Ki-67 were scored on tissue microarrays. Clinical information was obtained from medical records. Information on date, site, and histological characteristics of local and distant recurrences was obtained from medical records for both cases and controls. Results: Tumour tissue was analysed from 65 cases and 195 controls. Intense periductal lymphocytic infiltrate around DCIS was associated with an increased risk of later dying from breast cancer (OR 2.21. 95% c.i. 1.01 to 4.84). Tumours with more intense lymphocytic infiltrate had a lower T cell/B cell ratio. None of the other biomarkers correlated with increased risk of breast cancer death. Conclusion: The immune response to DCIS may influence the risk of dying from breast cancer.
- Open Access
- 15 September 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (18)
Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models
The tumor extracellular matrix (ECM) critically regulates cancer progression and treatment response. Expression of the basement membrane component collagen XVIII (ColXVIII) is induced in solid tumors, but its involvement in tumorigenesis has remained elusive. We show here that ColXVIII was markedly upregulated in human breast cancer (BC) and was closely associated with a poor prognosis in high-grade BCs. We discovered a role for ColXVIII as a modulator of epidermal growth factor receptor tyrosine kinase (ErbB) signaling and show that it forms a complex with ErbB1 and -2 (also known as EGFR and human epidermal growth factor receptor 2 [HER2]) and α6-integrin to promote cancer cell proliferation in a pathway involving its N-terminal portion and the MAPK/ERK1/2 and PI3K/AKT cascades. Studies using Col18a1 mouse models crossed with the mouse mammary tumor virus–polyoma virus middle T antigen (MMTV-PyMT) mammary carcinogenesis model showed that ColXVIII promoted BC growth and metastasis in a tumor cell–autonomous manner. Moreover, the number of mammary cancer stem cells was significantly reduced in the MMTV-PyMT and human cell models upon ColXVIII inhibition. Finally, ablation of ColXVIII substantially improved the efficacy of ErbB-targeting therapies in both preclinical models. In summary, ColXVIII was found to sustain the stemness properties of BC cells and tumor progression and metastasis through ErbB signaling, suggesting that targeting ColXVIII in the tumor milieu may have important therapeutic potential.
- 15 September 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (18)
Open AccessTargeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models
The tumor extracellular matrix (ECM) critically regulates cancer progression and treatment response. Expression of the basement membrane component collagen XVIII (ColXVIII) is induced in solid tumors, but its involvement in tumorigenesis has remained elusive. We show here that ColXVIII was markedly upregulated in human breast cancer (BC) and was closely associated with a poor prognosis in high-grade BCs. We discovered a role for ColXVIII as a modulator of epidermal growth factor receptor tyrosine kinase (ErbB) signaling and show that it forms a complex with ErbB1 and -2 (also known as EGFR and human epidermal growth factor receptor 2 [HER2]) and α6-integrin to promote cancer cell proliferation in a pathway involving its N-terminal portion and the MAPK/ERK1/2 and PI3K/AKT cascades. Studies using Col18a1 mouse models crossed with the mouse mammary tumor virus–polyoma virus middle T antigen (MMTV-PyMT) mammary carcinogenesis model showed that ColXVIII promoted BC growth and metastasis in a tumor cell–autonomous manner. Moreover, the number of mammary cancer stem cells was significantly reduced in the MMTV-PyMT and human cell models upon ColXVIII inhibition. Finally, ablation of ColXVIII substantially improved the efficacy of ErbB-targeting therapies in both preclinical models. In summary, ColXVIII was found to sustain the stemness properties of BC cells and tumor progression and metastasis through ErbB signaling, suggesting that targeting ColXVIII in the tumor milieu may have important therapeutic potential.
- Open Access
- 6 August 2022
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 195 (3) , 367-377
Correlation of tumour subtype with long-term outcome in small breast carcinomas: a Swedish population-based retrospective cohort study
Purpose: To investigate if molecular subtype is associated with outcome in stage 1 breast cancer (BC). Methods: Tissue samples from 445 women with node-negative BC ≤ 15 mm, treated in 1986–2004, were classified into surrogate molecular subtypes [Luminal A-like, Luminal B-like (HER2−), HER2-positive, and triple negative breast cancer (TNBC)]. Information on treatment, recurrences, and survival were gathered from medical records. Results: Tumour subtype was not associated with overall survival (OS). Luminal B-like (HER2−) and TNBC were associated with higher incidence of distant metastasis at 20 years (Hazard ratio (HR) 2.26; 95% CI 1.08–4.75 and HR 3.24; 95% CI 1.17–9.00, respectively). Luminal B-like (HER2−) and TNBC patients also had worse breast cancer-specific survival (BCSS), although not statistically significant (HR 1.53; 95% CI 0.70–3.33 and HR 1.89; 95% CI 0.60–5.93, respectively). HER2-positive BC was not associated with poor outcome despite no patient receiving HER2-targeted therapy, with most of these tumours being ER+. Conclusions: Stage 1 TNBC or Luminal B-like (HER2−) tumours behave more aggressively. Women with HER2+/ER+ tumours do not have an increased risk of distant metastasis or death, absent targeted treatment.
- 6 August 2022
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 195 (3) , 367-377
Open AccessCorrelation of tumour subtype with long-term outcome in small breast carcinomas: a Swedish population-based retrospective cohort study
Purpose: To investigate if molecular subtype is associated with outcome in stage 1 breast cancer (BC). Methods: Tissue samples from 445 women with node-negative BC ≤ 15 mm, treated in 1986–2004, were classified into surrogate molecular subtypes [Luminal A-like, Luminal B-like (HER2−), HER2-positive, and triple negative breast cancer (TNBC)]. Information on treatment, recurrences, and survival were gathered from medical records. Results: Tumour subtype was not associated with overall survival (OS). Luminal B-like (HER2−) and TNBC were associated with higher incidence of distant metastasis at 20 years (Hazard ratio (HR) 2.26; 95% CI 1.08–4.75 and HR 3.24; 95% CI 1.17–9.00, respectively). Luminal B-like (HER2−) and TNBC patients also had worse breast cancer-specific survival (BCSS), although not statistically significant (HR 1.53; 95% CI 0.70–3.33 and HR 1.89; 95% CI 0.60–5.93, respectively). HER2-positive BC was not associated with poor outcome despite no patient receiving HER2-targeted therapy, with most of these tumours being ER+. Conclusions: Stage 1 TNBC or Luminal B-like (HER2−) tumours behave more aggressively. Women with HER2+/ER+ tumours do not have an increased risk of distant metastasis or death, absent targeted treatment.
- Open Access
Type IV Collagen in Human Colorectal Liver Metastases—Cellular Origin and a Circulating Biomarker
Circulating type IV collagen (cCOL IV) is a potential biomarker for patients with colorectal liver metastases (CLM) who present with elevated levels of COL IV in both CLM tissue and circulation. This study aimed to establish the cellular origin of elevated levels of COL IV and analyze circulating COL IV in CLM patients. The cellular source was established through in situ hybridization, immunohistochemical staining, and morphological evaluation. Cellular expression in vitro was assessed by immunofluorescence. Tissue expression of COL IV-degrading matrix metalloproteinases (MMPs)-2, -7, -9, and -13 was studied with immunohistochemical staining. Plasma levels of COL IV in CLM patients and healthy controls were analyzed with ELISA. This study shows that cancer-associated fibroblasts (CAFs) express COL IV in the stroma of CLM and that COL IV is expressed in vitro by fibroblasts but not by tumor cells. MMP-2, -7, -9, and -13 are expressed in CLM tissue, mainly by hepatocytes and immune cells, and circulating COL IV is significantly elevated in CLM patients compared with healthy controls. Our study shows that stromal cells, not tumor cells, produce COL IV in CLM, and that circulating COL IV is elevated in patients with CLM.
Open AccessType IV Collagen in Human Colorectal Liver Metastases—Cellular Origin and a Circulating Biomarker
Circulating type IV collagen (cCOL IV) is a potential biomarker for patients with colorectal liver metastases (CLM) who present with elevated levels of COL IV in both CLM tissue and circulation. This study aimed to establish the cellular origin of elevated levels of COL IV and analyze circulating COL IV in CLM patients. The cellular source was established through in situ hybridization, immunohistochemical staining, and morphological evaluation. Cellular expression in vitro was assessed by immunofluorescence. Tissue expression of COL IV-degrading matrix metalloproteinases (MMPs)-2, -7, -9, and -13 was studied with immunohistochemical staining. Plasma levels of COL IV in CLM patients and healthy controls were analyzed with ELISA. This study shows that cancer-associated fibroblasts (CAFs) express COL IV in the stroma of CLM and that COL IV is expressed in vitro by fibroblasts but not by tumor cells. MMP-2, -7, -9, and -13 are expressed in CLM tissue, mainly by hepatocytes and immune cells, and circulating COL IV is significantly elevated in CLM patients compared with healthy controls. Our study shows that stromal cells, not tumor cells, produce COL IV in CLM, and that circulating COL IV is elevated in patients with CLM.
- 24 February 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (2) , e71
Prognostic value of type IV collagen expression in early breast cancer.
- 24 February 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (2) , e71
Prognostic value of type IV collagen expression in early breast cancer.
- Open Access
- 4 May 2021
- Published by Springer Nature in Research Square
Correlation of Tumour Subtype With Long-term Outcome in Small Breast Carcinomas: A Swedish Population-based Retrospective Cohort Study
Purpose: To investigate if molecular subtype is associated with outcome in stage 1 breast cancer (BC).Method: Tissue samples from 445 women with node-negative BC £15 mm, treated in 1986-2004, were classified into surrogate molecular subtypes (Luminal A-like, Luminal B-like, Her2-positive, and triple negative breast cancer (TNBC)). Information on treatment, recurrences and survival were gathered from medical records. Results: Tumour subtype was not associated with overall survival (OS). Luminal B-like and TNBC were associated with higher incidence of distant metastasis at 20 years. Luminal B-like and TNBC patients also had worse breast cancer specific survival (BCSS), although not statistically significant. Her2-positive BC was not associated with poor outcome despite no patient receiving Her2-targeted therapy.Conclusions: Stage 1 TNBC or Luminal B-like tumours behave more aggressively. Women with Her2+/ER+ tumours do not have an increased risk of distant metastasis or death, absent targeted treatment.
- 4 May 2021
- Published by Springer Nature in Research Square
Open AccessCorrelation of Tumour Subtype With Long-term Outcome in Small Breast Carcinomas: A Swedish Population-based Retrospective Cohort Study
Purpose: To investigate if molecular subtype is associated with outcome in stage 1 breast cancer (BC).Method: Tissue samples from 445 women with node-negative BC £15 mm, treated in 1986-2004, were classified into surrogate molecular subtypes (Luminal A-like, Luminal B-like, Her2-positive, and triple negative breast cancer (TNBC)). Information on treatment, recurrences and survival were gathered from medical records. Results: Tumour subtype was not associated with overall survival (OS). Luminal B-like and TNBC were associated with higher incidence of distant metastasis at 20 years. Luminal B-like and TNBC patients also had worse breast cancer specific survival (BCSS), although not statistically significant. Her2-positive BC was not associated with poor outcome despite no patient receiving Her2-targeted therapy.Conclusions: Stage 1 TNBC or Luminal B-like tumours behave more aggressively. Women with Her2+/ER+ tumours do not have an increased risk of distant metastasis or death, absent targeted treatment.